search
Back to results

Speckle Study: In Arterial, Mixed and Diabetic Foot Ulcers

Primary Purpose

Leg Ulcer

Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
gekoTM
Sponsored by
Firstkind Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Leg Ulcer focused on measuring Leg ulcers and use of geko device

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

In order to be eligible to enter the study patients must meet the following criteria:

  • Age ≥ 18 years
  • Intact healthy skin at the site of device application
  • Able to understand the Patient Information Sheet
  • Willing and able to give informed consent
  • Willing and able to follow the requirements of the protocol
  • Specific inclusion criteria for the subgroups:

Group A: Arterial Leg Ulcer

  • Defined as healing/non-healing Group B: Mixed Leg Ulcer (only to be done once Arterial leg ulcers show change in flux)
  • ABPI of <0.8-0.6 Group C: Diabetic Foot Ulcer - neuropathic
  • On clinical inspection present as neuropathic Group D: Diabetic Foot Ulcer - neuroischemic
  • On clinical inspection present as neuroischemic

Exclusion Criteria:

Patients will not be admitted to the study if they meet any of the following exclusion criteria:

  • Significant (not colonialization) Wound infection either acute or chronic??
  • History of significant haematological disorders or DVT with the preceding six months
  • Pregnant
  • Pacemakers or implantable defibrillators
  • Use of any other neuro-modulation device
  • Current use of TENS in pelvic region, back or legs
  • Use of investigational drug or device within the past 4 weeks that may interfere with this study
  • Recent surgery that may affect the study (such as abdominopelvic, or lower limb) in the opinion of the investigator.
  • Recent trauma to the lower limbs that will prevent stimulation of the leg with geko (non-responders)
  • Size of leg incompatible with the geko™ device., i.e prevents device from stimulating the common peroneal nerve
  • obesity (BMI > 35)
  • Any medication deemed to be significant by the Investigator
  • Specific exclusion criteria for different subgroups:

Group A: Arterial Leg Ulcer - Mixed leg ulcer, diabetic foot ulcer or diabetic foot ulcer with neuroischaemic element.

Group B: Mixed Leg Ulcer

- Arterial leg ulcer, diabetic foot ulcer or diabetic foot ulcer with neuroischaemic element.

Group C: Diabetic Foot Ulcer - Mixed leg ulcer, Arterial leg ulcer, or diabetic foot ulcer with neuroischaemic element.

Group D: Diabetic Foot Ulcer - neuroischemic

- Mixed leg ulcer, Arterial leg ulcer or diabetic foot ulcer

Sites / Locations

  • Glenfield Hospital
  • Aneurin Bevan Local Health Board
  • Welsh wound Innovation Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Group A: Arterial Leg Ulcer

Group B: Mixed Leg Ulcer

Group C: Diabetic Foot Ulcer - neuropathic

Group D: Diabetic Foot Ulcer - neuroischemic

Arm Description

Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period

only to be done once Arterial leg ulcers show change in flux ABPI of <0.8-0.6

On clinical inspection present as neuropathic

On clinical inspection present as neuroischemic

Outcomes

Primary Outcome Measures

Microcirculatory flux in the lower limb of the different subgroups with geko device on.
Measurements of microcirculatory flux in the lower limb of the different subgroups with geko device on.

Secondary Outcome Measures

Temperature variation
measurements of Temperature over same time period as speckle device using the Exergen DermaTemp model DT1001.
Adverse Events
study rate of adverse events

Full Information

First Posted
June 5, 2017
Last Updated
August 18, 2023
Sponsor
Firstkind Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT03186560
Brief Title
Speckle Study: In Arterial, Mixed and Diabetic Foot Ulcers
Official Title
A Single Centre Open Label Study Measuring Microcirculatory Flux Using Speckle Imaging Device, in Patients With Arterial, Mixed and Diabetic Foot Ulcers Using gekoTM Neuromuscular Electrostimulation (NMES)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Terminated
Why Stopped
Difficulties with recruitment
Study Start Date
February 12, 2018 (Actual)
Primary Completion Date
January 26, 2023 (Actual)
Study Completion Date
January 26, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Firstkind Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a single centre open label study measuring microcirculatory flux using Speckle imaging Device. Microcirculation will be measured using laser speckle contrast imaging, at baseline and with the device active for 30 minutes in the wound, peri-wound and other point on the lower leg. The same procedure will be done on all the different patient groups. Temperature variations can be assessed using Infrared Temperature Scanner (Exergen DermaTemp DT1001), a measurement will be taken at baseline, and then at 5 minutes interval during the 30 minutes activity of the device.
Detailed Description
The most common underlying etiologic factors responsible for chronic delayed healing among lower extremity wounds encountered in the outpatient clinic are chronic venous insufficiency (CVI), diabetic neuropathy, and arterial insufficiency (AI). One or more of these factors can be identified in more than 90% of chronic lower extremity ulcers, and treatment protocols have been designed to manage wounds of each type to maximize healing potential. It is important to remember that multiple factors may coexist in any individual patient with a chronic wound, complicating management and hindering the healing process. Recently, it has been reported that the neuroischemic diabetic foot ulcer is now more common than nonischemic neuropathic diabetic foot ulcers, as arterial insufficiency promoted by poorly controlled diabetes complicates already impaired healing present in patients with diabetes. Chronic leg ulcers are painful, debilitating wounds that place a significant burden on the patient, their family, and healthcare resources. Treating leg ulcers can present a significant challenge to clinicians, who currently have a limited range of treatments at their disposal. The mainstay of treatment is compression bandaging, ambulation and elevation at rest. In patients with mobility deficits, or in those who are unable to tolerate compression bandaging, ulcers may deteriorate and never heal. Accordingly, there is a need for novel, alternative devices or strategies that can be used to complement or replace compression therapy. Numerous pathophysiological and metabolic factors can affect wound healing and result in a poor outcome. They include local causes such as oedema, ischemia, tissue hypoxia, infection, necrosis and growth factor imbalance, as well as systemic causes including metabolic disease, nutritional status general perfusion disturbances and pre-existing illness. These factors alter the wound repair environment, impede healing and increase the risk of chronic wound development. All healing processes including, inflammatory cell influx, fibroblast migration, and collagen and extracellular matrix deposition, are delayed in this situation, leading to prolonged wound healing. Any wound management should assist the healing process and optimise the patient's blood flow to the wound area4. An acute wound in a stable patient with normal blood flow should heal successfully. Anything that compromises tissue oxygen delivery, such as poor vascularisation, will impede healing. There is a strong scientific basis for oxygen treatment as prophylaxis against infection; to facilitate wound closure and to prevent amputation in wounded patients. Oxygen delivery is a critical element for the healing of wounds. Hypoxemia, caused by disrupted vasculature, is a key limiting factor against wound healing. The link between compromised circulation and ulceration is well established and well described. Chronic venous insufficiency is a direct cause of ulceration. Diabetic foot ulcer is a major complication of diabetes mellitus, and probably the major component of the diabetic foot. Diabetes mellitus is one such metabolic disorder that impedes the normal steps of the wound healing process. Many studies show a prolonged inflammatory phase in diabetic wounds, which causes a delay in the formation of mature granulation tissue and a parallel reduction in wound tensile strength. Treatment of diabetic foot ulcers should include: blood sugar control, removing dead tissue from the wound, dressings, and removing pressure from the wound through techniques such as total contact casting. Surgery in some cases may improve outcomes. Hyperbaric oxygen therapy may also help but is expensive. It occurs in 15% of people with diabetes and precedes 84% of all diabetes-related lower-leg amputations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leg Ulcer
Keywords
Leg ulcers and use of geko device

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Geko device will be provided
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
34 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A: Arterial Leg Ulcer
Arm Type
Active Comparator
Arm Description
Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period
Arm Title
Group B: Mixed Leg Ulcer
Arm Type
Active Comparator
Arm Description
only to be done once Arterial leg ulcers show change in flux ABPI of <0.8-0.6
Arm Title
Group C: Diabetic Foot Ulcer - neuropathic
Arm Type
Active Comparator
Arm Description
On clinical inspection present as neuropathic
Arm Title
Group D: Diabetic Foot Ulcer - neuroischemic
Arm Type
Active Comparator
Arm Description
On clinical inspection present as neuroischemic
Intervention Type
Device
Intervention Name(s)
gekoTM
Intervention Description
The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
Primary Outcome Measure Information:
Title
Microcirculatory flux in the lower limb of the different subgroups with geko device on.
Description
Measurements of microcirculatory flux in the lower limb of the different subgroups with geko device on.
Time Frame
35 minutes
Secondary Outcome Measure Information:
Title
Temperature variation
Description
measurements of Temperature over same time period as speckle device using the Exergen DermaTemp model DT1001.
Time Frame
35 minutes
Title
Adverse Events
Description
study rate of adverse events
Time Frame
35 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: In order to be eligible to enter the study patients must meet the following criteria: Age ≥ 18 years Intact healthy skin at the site of device application Able to understand the Patient Information Sheet Willing and able to give informed consent Willing and able to follow the requirements of the protocol Specific inclusion criteria for the subgroups: Group A: Arterial Leg Ulcer Defined as healing/non-healing Group B: Mixed Leg Ulcer (only to be done once Arterial leg ulcers show change in flux) ABPI of <0.8-0.6 Group C: Diabetic Foot Ulcer - neuropathic On clinical inspection present as neuropathic Group D: Diabetic Foot Ulcer - neuroischemic On clinical inspection present as neuroischemic Exclusion Criteria: Patients will not be admitted to the study if they meet any of the following exclusion criteria: Significant (not colonialization) Wound infection either acute or chronic?? History of significant haematological disorders or DVT with the preceding six months Pregnant Pacemakers or implantable defibrillators Use of any other neuro-modulation device Current use of TENS in pelvic region, back or legs Use of investigational drug or device within the past 4 weeks that may interfere with this study Recent surgery that may affect the study (such as abdominopelvic, or lower limb) in the opinion of the investigator. Recent trauma to the lower limbs that will prevent stimulation of the leg with geko (non-responders) Size of leg incompatible with the geko™ device., i.e prevents device from stimulating the common peroneal nerve obesity (BMI > 35) Any medication deemed to be significant by the Investigator Specific exclusion criteria for different subgroups: Group A: Arterial Leg Ulcer - Mixed leg ulcer, diabetic foot ulcer or diabetic foot ulcer with neuroischaemic element. Group B: Mixed Leg Ulcer - Arterial leg ulcer, diabetic foot ulcer or diabetic foot ulcer with neuroischaemic element. Group C: Diabetic Foot Ulcer - Mixed leg ulcer, Arterial leg ulcer, or diabetic foot ulcer with neuroischaemic element. Group D: Diabetic Foot Ulcer - neuroischemic - Mixed leg ulcer, Arterial leg ulcer or diabetic foot ulcer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Bosanquet
Organizational Affiliation
Aneurin Bevan University Health Board
Official's Role
Principal Investigator
Facility Information:
Facility Name
Glenfield Hospital
City
Leicester
ZIP/Postal Code
LE3 9QP
Country
United Kingdom
Facility Name
Aneurin Bevan Local Health Board
City
Newport
ZIP/Postal Code
NP18 3XG
Country
United Kingdom
Facility Name
Welsh wound Innovation Centre
City
Wales
ZIP/Postal Code
cf72 8ux
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32768540
Citation
Bosanquet DC, Ivins N, Jones N, Harding KG. Microcirculatory Flux and Pulsatility in Arterial Leg Ulcers is Increased by Intermittent Neuromuscular Electrostimulation of the Common Peroneal Nerve. Ann Vasc Surg. 2021 Feb;71:308-314. doi: 10.1016/j.avsg.2020.07.030. Epub 2020 Aug 5.
Results Reference
derived

Learn more about this trial

Speckle Study: In Arterial, Mixed and Diabetic Foot Ulcers

We'll reach out to this number within 24 hrs